Business Context and Reporting Period
Syndax Pharmaceuticals, Inc. (SNDX) filed this Form 8-K on February 7, 2020, to disclose the entry into a material definitive agreement. The Company is a Delaware corporation focused on clinical-stage pharmaceutical development, specifically highlighting its Phase 3 clinical trial of entinostat (E2112) for advanced breast cancer.
Key Financial Metrics and Debt Structure
The filing details a new loan and security agreement with Hercules Capital, Inc., establishing the following financial terms:
- Total Borrowing Capacity: Up to $30.0 million.
- Initial Funding: A term loan of $20.0 million funded on February 7, 2020.
- Contingent Funding: An additional term loan of up to $10.0 million (Tranche 2 Advance) available through December 15, 2020, subject to investment committee approval.
- Interest Rate: The greater of 9.5% or 5.10% plus the Wall Street Journal prime rate.
- Repayment Terms: Monthly interest-only payments through October 1, 2021, or April 1, 2022 if a specific clinical performance milestone is met. Principal and interest are repayable in equal monthly installments thereafter until maturity.
- Maturity Date: September 1, 2023, or March 1, 2024 if the performance milestone is achieved.
- Fees and Charges: $100,000 facility charge paid at closing; $50,000 facility charge due upon Tranche 2 Advance; final payment of up to $998,000 due at maturity.
- Collateral: Substantially all personal property and assets, excluding intellectual property.
- Covenants: Includes a minimum cash covenant of $12.5 million effective September 30, 2020, and restrictions on indebtedness, liens, and distributions.
The filing does not provide current revenue, profit, cash flow, or margin data, as this is a current report regarding a specific transaction rather than a periodic financial statement.
Material Changes and Unusual Items
The primary material change is the incurrence of significant new debt obligations. The loan structure is uniquely tied to the clinical success of the Company's lead asset, entinostat. Achievement of the primary efficacy endpoint in the Phase 3 trial (the "Performance Milestone") extends the interest-only period and the loan maturity date by six months. Failure to meet this milestone accelerates the repayment schedule.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement is designed to provide capital to support clinical development, with terms contingent on the success of the entinostat Phase 3 trial.
Risks and Contingencies:
- Default Risk: Events of default include payment defaults, covenant breaches, and material adverse effects. A default triggers an additional 5.0% interest rate and immediate acceleration of all obligations.
- Liquidity Constraints: The Company must maintain a minimum cash balance of $12.5 million starting September 30, 2020.
- Prepayment Penalties: Prepayment is allowed but subject to premiums ranging from 1.0% to 2.0% depending on the timing relative to the funding date.
- Collateral Limitations: While intellectual property is excluded from collateral, the negative pledge restricts the Company from placing liens on IP or other assets.
Key Facts for Investor Verification
- Verify the Company's current cash position against the $12.5 million minimum cash covenant effective September 30, 2020.
- Monitor the progress of the entinostat (E2112) Phase 3 clinical trial, as its success directly impacts loan maturity and repayment terms.
- Confirm whether the $10.0 million Tranche 2 Advance is drawn, as this increases total debt exposure.
- Review the upcoming Form 10-Q for the quarter ended March 31, 2020, for the full text of the Loan Agreement and updated financial statements.